BR0108376A - Composto, polepeptìdeo, ácido nucleico, vetor, vìrus recombinante defectivo, anticorpo ou fragmento ou derivado de anticorpo, composição farmacêutica, processos para a seleção ou a caracterização de moléculas ativas e para a produção de um composto peptìdico, proteìna, célula, e, mamìfero não-humano - Google Patents

Composto, polepeptìdeo, ácido nucleico, vetor, vìrus recombinante defectivo, anticorpo ou fragmento ou derivado de anticorpo, composição farmacêutica, processos para a seleção ou a caracterização de moléculas ativas e para a produção de um composto peptìdico, proteìna, célula, e, mamìfero não-humano

Info

Publication number
BR0108376A
BR0108376A BR0108376-7A BR0108376A BR0108376A BR 0108376 A BR0108376 A BR 0108376A BR 0108376 A BR0108376 A BR 0108376A BR 0108376 A BR0108376 A BR 0108376A
Authority
BR
Brazil
Prior art keywords
compound
antibody
protein
mammal
characterization
Prior art date
Application number
BR0108376-7A
Other languages
English (en)
Inventor
Hana Koutnikova
Alexis Brice
Alain Fournier
Laurent Pradier
Catherine Prades
Isabelle Arnould-Reguigne
Marie-Francoise Rosier-Montus
Olga Corti
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0001980A external-priority patent/FR2805266B1/fr
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Publication of BR0108376A publication Critical patent/BR0108376A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSTO, POLIPEPTìDEO, áCIDO NUCLEICO, VETOR, VìRUS RECOMBINANTE DEFECTIVO, ANTICORPO OU FRAGMENTO OU DERIVADO DE ANTICORPO, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA A SELEçãO OU A CARACTERIZAçãO DE MOLéCULAS ATIVAS E PARA A PRODUçãO DE UM COMPOSTO PEPTìDICO, PROTEINA, CéLULA, E, MAMìFERO NãO-HUMANO". A presente invenção refere-se a compostos inéditos e a suas utilizações, principalmente farmacêuticas, diagnósticas ou como alvos farmacológicos. Mais particularmente, a presente invenção refere-se a uma proteína inédita, denominada PAP1, e também a peptídeos e compostos inéditos capazes de modular pelo menos parcialmente a atividade da parkina.
BR0108376-7A 2000-02-17 2001-02-15 Composto, polepeptìdeo, ácido nucleico, vetor, vìrus recombinante defectivo, anticorpo ou fragmento ou derivado de anticorpo, composição farmacêutica, processos para a seleção ou a caracterização de moléculas ativas e para a produção de um composto peptìdico, proteìna, célula, e, mamìfero não-humano BR0108376A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0001980A FR2805266B1 (fr) 2000-02-17 2000-02-17 Compositions utilisables pour reguler l'activite de la parkine
US19848900P 2000-04-18 2000-04-18
PCT/FR2001/000461 WO2001060857A2 (fr) 2000-02-17 2001-02-15 Compositions utilisables pour reguler l'activite de la parkine

Publications (1)

Publication Number Publication Date
BR0108376A true BR0108376A (pt) 2003-03-11

Family

ID=26212182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108376-7A BR0108376A (pt) 2000-02-17 2001-02-15 Composto, polepeptìdeo, ácido nucleico, vetor, vìrus recombinante defectivo, anticorpo ou fragmento ou derivado de anticorpo, composição farmacêutica, processos para a seleção ou a caracterização de moléculas ativas e para a produção de um composto peptìdico, proteìna, célula, e, mamìfero não-humano

Country Status (14)

Country Link
US (2) US7132396B2 (pt)
EP (1) EP1259606B1 (pt)
KR (1) KR100811926B1 (pt)
AT (1) ATE466083T1 (pt)
AU (1) AU2001235696A1 (pt)
BR (1) BR0108376A (pt)
CA (1) CA2400256C (pt)
CY (1) CY1111004T1 (pt)
DE (1) DE60141948D1 (pt)
IL (3) IL151211A0 (pt)
MX (1) MXPA02007869A (pt)
NO (1) NO20023914L (pt)
NZ (1) NZ520802A (pt)
WO (1) WO2001060857A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051902A1 (en) * 2001-12-14 2003-06-26 Incyte Genomics, Inc. Neurotransmission-associated proteins
US7927786B2 (en) * 2003-02-18 2011-04-19 Cedars-Sinai Medical Center Parkin interacting polypeptides and methods of use
PL2195645T3 (pl) * 2007-09-11 2014-12-31 Cancer Prevention & Cure Ltd Metoda wspomagająca diagnostykę i terapię astmy i rak płuc
CN109297780B (zh) * 2018-10-23 2021-01-01 东华理工大学 一种液塑限联合测定法中的取样方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2449501A (en) * 1999-12-21 2001-07-03 Incyte Genomics, Inc. Vesicle trafficking proteins
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030220240A1 (en) * 2000-12-21 2003-11-27 Tang Y. Tom Vesicle trafficking proteins

Also Published As

Publication number Publication date
US7132396B2 (en) 2006-11-07
IL193310A (en) 2011-12-29
EP1259606A2 (fr) 2002-11-27
NO20023914D0 (no) 2002-08-16
KR100811926B1 (ko) 2008-03-10
CA2400256A1 (fr) 2001-08-23
US8273548B2 (en) 2012-09-25
AU2001235696A1 (en) 2001-08-27
ATE466083T1 (de) 2010-05-15
DE60141948D1 (de) 2010-06-10
IL193310A0 (en) 2011-08-01
EP1259606B1 (fr) 2010-04-28
CY1111004T1 (el) 2015-06-11
NO20023914L (no) 2002-10-11
IL151211A (en) 2010-05-31
CA2400256C (fr) 2014-09-09
US20020155577A1 (en) 2002-10-24
US20060287230A1 (en) 2006-12-21
MXPA02007869A (es) 2003-02-10
IL151211A0 (en) 2003-04-10
KR20020089352A (ko) 2002-11-29
WO2001060857A2 (fr) 2001-08-23
NZ520802A (en) 2005-02-25
WO2001060857A3 (fr) 2002-06-20

Similar Documents

Publication Publication Date Title
Camporeale et al. K8 and K12 are biotinylated in human histone H4
Zhang et al. Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody
Taddese et al. In vitro degradation of human tropoelastin by MMP-12 and the generation of matrikines from domain 24
Heinz et al. The action of neutrophil serine proteases on elastin and its precursor
ATE476654T1 (de) Plattform für protein-profiling
JP2009523844A (ja) 新規なペプチド及びこれの用途
ATE306498T1 (de) Von zellen präsentierte peptide
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
Munawar et al. Isolation and characterization of Bradykinin potentiating peptides from Agkistrodon bilineatus venom
Pasch et al. PEGylated sequence-controlled macromolecules using supramolecular binding to target the Taspase1/Importin α interaction
WO2007048638A3 (de) Der botulinus neurotoxin a proteinrezeptor und seine anwendungen
Fukai et al. Rat plasma fibronectin contains two distinct chemotactic domains for fibroblastic cells
Goolcharran et al. Comparison of the rates of deamidation, diketopiperazine formation, and oxidation in recombinant human vascular endothelial growth factor and model peptides
BR0108376A (pt) Composto, polepeptìdeo, ácido nucleico, vetor, vìrus recombinante defectivo, anticorpo ou fragmento ou derivado de anticorpo, composição farmacêutica, processos para a seleção ou a caracterização de moléculas ativas e para a produção de um composto peptìdico, proteìna, célula, e, mamìfero não-humano
Sturrock et al. Assignment of free and disulfide-bonded cysteine residues in testis angiotensin-converting enzyme: functional implications
Toyama et al. Structure–function relationship of new crotamine isoform from the Crotalus durissus cascavella
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
EP1766011A1 (en) Polypeptide ligands containing linkers
Baglia et al. The Apple 1 and Apple 4 domains of factor XI act synergistically to promote the surface-mediated activation of factor XI by factor XIIa
US20100212030A1 (en) Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
WO2005030798A3 (en) TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
Chen et al. Functional interrogation of the n-terminal lid of MDMX in p53 binding via native chemical ligation
Fenselau et al. Mass spectrometric analysis of proteins
Caetano et al. Expression and purification of recombinant vascular endothelial-statin
Pfeffer-Hennig et al. Three dimensional structure of the antibiotic bacitracin A complexed to two different subtilisin proteases: Novel mode of enzyme inhibition

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time